Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.
InDex Pharmaceuticals Holding AB (publ) today announced that patient enrolment was completed in the dose optimisation study CONDUCT, which is evaluating cobitolimod for the treatment of moderate to severe ulcerative colitis.
An insightful interview with NDA’s Claes Buxfeldt, HTA Director, entitled “Observations of a market access expert” featured in Aprils edition of Pharmafocus.
Welcome to NDA’s free Lunch seminar on Tuesday 30th April 12:00- 14:00 on Interactions with Agencies During Drug Development
Elagolix, in combination with add-back therapy, achieved statistically significant reduction in heavy menstrual bleeding associated with uterine fibroids compared to placebo
Saxenda® is the first and only FDA-approved medicine in a pen indicated to help adults lose weight and keep it off
In U-ACHIEVE, upadacitinib (15/30/45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all ranked secondary endpoints, including endoscopic improvement, clinical remission (per Full Mayo Score) and clinical response, in patients with moderately to severely active ulcerative colitis